Aardvark Therapeutics Share Price (NASDAQ: AARD)

Aardvark Therapeutics Stock Performance

as on October 4, 2025 at 1:29 am IST

Day's Low
Day's High
$15.21
Day's Price Range
$16.3
$16.07
5.35%
Downside
1.43%
Upside
52 Week's Low
52 Week's High
$4.88
52-Week Price Range
$19.58
$16.07
69.63%
Downside
21.84%
Upside

Aardvark Therapeutics share price movements today

Previous Close: $15.37
Open: $15.37
Volume: 482.4K
Day's Low - High: $15.21 - $16.3
52 Week Low - High: $4.88 - $19.58

Aardvark Therapeutics Historical Returns

1 Month Return: + 89.4 %
3 Month Return: + 15.52 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Aardvark Therapeutics Stock Fundamentals & Key Indicators

Check Aardvark Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$284.4M

EPS (TTM)

Dividend Yield

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

Return On Equity TTM

1822000.00%

Aardvark Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Aardvark Therapeutics with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Aardvark Therapeutics	NA	$284.4M	NA	NA	0.00%
Beone Medicines Ltd	NA	$40.5B	NA	NA	-3.89%
Alnylam Pharmaceuticals, Inc.	BUY	$60.4B	236.34%	-505.15	-12.96%
Vertex Pharmaceuticals Incorporated	BUY	$104.8B	54.64%	29.06	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$63.6B	6.23%	15.13	31.37%

Aardvark Therapeutics Stock’s Investor Sentiment and Interest

Search interest for Aardvark Therapeutics Stock has increased by 50% in the last 30 days, reflecting an upward trend in search activity.

Time period: September 5, 2025 to October 5, 2025

Change:50% versus previous 30 day period

Aardvark Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	-	-	-	-	-	-	-	-
Gross Profit	0	0	0	0	0	-	0	-
Operating Income	-1	-2	-2	-6	-5	-9	-10	-15
EBITDA	-1	-2	-2	-6	-5	-9	-10	-15
Interest Expense	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0
Income Before Tax	-2	-2	-2	-5	-4	-8	-9	-14
Income Tax Expense	-	-	-	-	-	-	-	-
Net Income	-2	-2	-2	-5	-4	-8	-9	-14
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Aardvark Therapeutics Annual Profit & Loss

All numbers in Millions USD

	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-
Gross Profit	0	0	0
Operating Income	-11	-7	-22
EBITDA	-10	-7	-20
Interest Expense	-	-	-
Depreciation	0	0	0
Income Before Tax	-13	-7	-20
Income Tax Expense	-	-	-
Net Income	-13	-7	-20
Net Profit Margin	0.00%	0.00%	0.00%

Aardvark Therapeutics Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-2	-2	-5	-4	-8	-9	-14
Operating Cash Flow	-1	-2	-4	-3	-7	-11	-9
Investing Cash Flow	-	0	0	0	-11	-112	9
Financing Cash Flow	-	-	82	0	-1	88	0
Change in Cash	-1	-2	78	-3	-20	-35	0

Aardvark Therapeutics Annual Cash Flow

All numbers in Millions USD

	Dec 2023	Dec 2024
Net Income	-7	-20
Operating Cash Flow	-5	-18
Investing Cash Flow	-	-11
Financing Cash Flow	-	81
Change in Cash	-5	51

Insights on Aardvark Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 1 month, AARD stock has moved up by 50.0%

About Aardvark Therapeutics

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).

Organisation	Aardvark Therapeutics
Headquarters	4370 La Jolla Village Drive, San Diego, CA, United States, 92122
CEO	Dr. Tien-Li Lee M.D.
E-voting on shares	Click here to vote

Key Management of Aardvark Therapeutics

Name	Title
Dr. Zhenhuan Zheng Ph.D.	Chief Research Officer
Mr. Ron Lewis II, Ph.D.	VP & Head of CMC
Dr. Tien-Li Lee M.D.	CEO, Secretary & Director
Dr. Bryan Jones Ph.D.	Chief Operating Officer
Mr. Nelson B. Sun M.B.A.	Chief Financial Officer
Dr. Dvorit Samid Ph.D.	Executive Vice President of Medical Affairs
Dr. Manasi Sinha Jaiman M.D., M.P.H.	Chief Medical Officer
Dr. Timothy J. Kieffer Ph.D.	Chief Scientific Officer
Mr. Christian Zapf J.D.	General Counsel
Dr. Terrie Kellmeyer Ph.D.	Senior Vice President of Regulatory Affairs

FAQs

What is Aardvark Therapeutics share price today?

Aardvark Therapeutics share price today is $16.07 as on October 4, 2025 at 1:29 am IST at the close of the market. Aardvark Therapeutics share today touched a day high of $16.3 and a low of $15.21.

What is the 52 week high and 52 week low for Aardvark Therapeutics share?

Aardvark Therapeutics share touched a 52 week high of $19.58 on February 20, 2025 and a 52 week low of $4.88 on April 9, 2025. Aardvark Therapeutics stock price today i.e. October 4, 2025 at 1:29 am IST is closed at $16.07,which is 17.93% down from its 52 week high and 229.30% up from its 52 week low.

What is Aardvark Therapeutics's market capitalisation today?

Aardvark Therapeutics market capitalisation is $0.00T as on October 4, 2025 at 1:29 am IST.

How to invest in Aardvark Therapeutics Stock (AARD) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Aardvark Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Aardvark Therapeutics Shares that will get you 0.0933 shares as per Aardvark Therapeutics share price of $16.07 per share as on October 4, 2025 at 1:29 am IST.

What is the minimum amount required to buy Aardvark Therapeutics Stock (AARD) from India?

Indian investors can start investing in Aardvark Therapeutics (AARD) shares with as little as ₹88.775 or $1 (as of October 5, 2025 at 11:36 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹887.75 in Aardvark Therapeutics stock (as per the Rupee-Dollar exchange rate as on October 5, 2025 at 11:36 pm IST). Based on Aardvark Therapeutics share’s latest price of $16.07 as on October 4, 2025 at 1:29 am IST, you will get 0.6223 shares of Aardvark Therapeutics. Learn more about fractional shares .